PHYSIMED

The computed 12-month bankruptcy probability of PHYSIMED is 8.4% (elevated). For PHYSIMED, at least two filing cycles of the annual accounts are missing. The 2022 annual accounts show equity of €523,146 and a net result of -€16,942. Equity remains stable across the filed financial years (±2% per year). Its solvency ranks better than 93% of 1,073 sector peers (NACE 71, financial year 2022). The company has been active since 2004 and the Belgian Official Gazette contains no insolvency or warning signals.